Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering.
The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating ...
Viridian Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, founded in 2006. Formerly known as Miragen Therapeutics, the company rebranded in January 2021. Viridian is dedicated to discovering, developing, and commercializing treatments for serious and rare diseases, utilizing its expertise in antibody discovery and protein engineering.
The company’s product pipeline includes Veligrotug (VRDN-001), a monoclonal antibody in Phase 3 clinical trials for thyroid eye disease, and VRDN-003, a next-generation IGF-1R monoclonal antibody also in Phase 3 trials for the same condition. Additionally, Viridian is developing a portfolio of engineered anti-FcRn inhibitors, such as VRDN-006 and VRDN-008, aimed at treating various autoimmune diseases. Viridians mission is to deliver transformative therapies for patients with underserved diseases, emphasizing innovation and patient-centricity.
-
Number of Employees:
100-250
-
Annual Revenue:
$0-1 Million